


## NS11394

Cat. No.:	HY-11048
CAS No.:	951650-22-9
Molecular Formula:	C <sub>23</sub> H <sub>19</sub> N <sub>3</sub> O
Molecular Weight:	353.42
Target:	GABA Receptor
Pathway:	Membrane Transporter/Ion Channel; Neuronal Signaling
Storage:	<div> <div>Powder</div> <div>-20°C    3 years</div> <div>4°C    2 years</div> </div> <div> <div>In solvent</div> <div>-80°C    2 years</div> <div>-20°C    1 year</div> </div>



### SOLVENT & SOLUBILITY

In Vitro	DMSO : 100 mg/mL (282.95 mM; Need ultrasonic)					
	Preparing Stock Solutions	<div><div>Solvent</div><div>Concentration</div></div>	Mass	1 mg	5 mg	10 mg
		1 mM		2.8295 mL	14.1475 mL	28.2949 mL
		5 mM		0.5659 mL	2.8295 mL	5.6590 mL
		10 mM		0.2829 mL	1.4147 mL	2.8295 mL
Please refer to the solubility information to select the appropriate solvent.						
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (7.07 mM); Clear solution					
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (7.07 mM); Clear solution					
	3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (7.07 mM); Clear solution					

### BIOLOGICAL ACTIVITY

Description	NS11394 is an orally active and unique subtype-selective GABA <sub>A</sub> positive allosteric receptor (PAM), with a K <sub>i</sub> of ~0.5 nM. NS11394 shows a selectivity profile in the order of GABA <sub>A</sub> -5 > α3 > α2 > α1-containing receptors. NS11394 has anxiolytic and anti-inflammatory properties <sup>[1][2][3]</sup> .
In Vivo	NS11394 (1-120 mg/kg) selectively attenuates injury-induced nociceptive behaviors in the formalin test <sup>[2]</sup> . NS11394 (1-10 mg/kg) markedly attenuates the deficit in hindpaw weight bearing [F(4,61) = 7.569, p < 0.001] in CFA rats <sup>[2]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Adult male Sprague-Dawley rats <sup>[2]</sup> .
Dosage:	1-120 mg/kg.
Administration:	Orally.
Result:	Significantly attenuated motor function compared with corresponding vehicle responses. Significantly reduced flinching behavior during interphase [ $F(3,30) = 4.139$ , $p < 0.05$ ] and the second phase [ $F(3,30) = 11.033$ , $p < 0.001$ ] of the formalin test compared with vehicle treatment indicative of a selective effect on injury-induced nociceptive transmission.

## CUSTOMER VALIDATION

- Cell. 2017 Jan 12;168(1-2):86-100.e15.
- Cell Rep. 2020 Jan 21;30(3):602-610.e6.
- Biochem Pharmacol. 2018 Dec;158:339-358.

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

## REFERENCES

- [1]. N. R. Mirza, et al. NS11394 [3'-(5-(1-Hydroxy-1-methyl-ethyl)-benzimidazol-1-yl)-biphenyl-2-carbonitrile], a Unique Subtype-Selective GABAA Receptor Positive Allosteric Modulator: In Vitro Actions, Pharmacokinetic Properties and in Vivo Anxiolytic Efficacy
- [2]. G. Munro, J. A., et al. Comparison of the Novel Subtype-Selective GABAA Receptor-Positive Allosteric Modulator NS11394 [3'-(5-(1-Hydroxy-1-methyl-ethyl)-benzimidazol-1-yl)-biphenyl-2-carbonitrile] with Diazepam, Zolpidem, Bretazenil, and Gaboxadol in Rat
- [3]. Martine Hofmann, et al. Assessment of the effects of NS11394 and L-838417,  $\alpha 2/3$  subunit-selective GABAA receptor-positive allosteric modulators, in tests for pain, anxiety, memory and motor function. Behavioural Pharmacology 2012, 23:790–801.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA